Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients
Sequential treatment with radium- 223 prior to Lu- 177-PSMA does not affect PFS or OS outcomes in mCRPC patients. Therefore, this real-world cohort suggests that both radiopharmaceuticals can be administered within mCRPC treatment algorithm.
Authors
- Daniel Groener (ORCID: https://orcid.org/0000-0001-7927-6226)
- Markus Graefen
- Carolin Siech (ORCID: https://orcid.org/0000-0002-5460-4171)
- Tobias Maurer (ORCID: https://orcid.org/0000-0002-5660-7691)
- Lena Theißen (ORCID: https://orcid.org/0000-0001-6791-8105)
- Séverine Banek
- Maximilian C. Kriegmair (ORCID: https://orcid.org/0000-0002-0344-3590)
- Mike Wenzel (ORCID: https://orcid.org/0000-0002-4338-0889)
- Benedikt Hoeh (ORCID: https://orcid.org/0000-0002-4238-6584)
- Felix K. H. Chun (ORCID: https://orcid.org/0000-0002-1644-2677)
- Philipp Mandel
- Georg Salomon
Institutions
- Goethe University Frankfurt (DE)
- Universität Hamburg (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- University Hospital Frankfurt (DE)
- University Medical Centre Mannheim (DE)
- Urologische Klinik München (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1007/s00259-025-07256-5
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56